KPV Peptide: Comprehensive Research Overview

Document Version: 1.0 Last Updated: December 2024 Classification: Research Paper - Peptide Therapeutics

Goal Relevance:

• Reduce gut inflammation and improve symptoms related to inflammatory bowel disease (IBD)
• Speed up recovery from wounds and improve skin conditions like eczema and psoriasis
• Manage chronic inflammation associated with autoimmune diseases or metabolic disorders
• Enhance gut health by promoting mucosal barrier integrity and reducing inflammation
• Support skin healing and reduce microbial colonization in wounds

1. Executive Summary

Overview

KPV is a tripeptide consisting of three amino acids in the specific sequence Lysine-Proline-Valine (Lys-Pro-Val), corresponding to positions 11-13 of the alpha-melanocyte stimulating hormone (α-MSH) tridecapeptide. As the C-terminal fragment of α-MSH, KPV represents the minimal bioactive sequence required for potent anti-inflammatory activity, exhibiting effects equal to or exceeding those of the full-length 13-amino acid parent hormone.

Molecular Identity

• Amino Acid Sequence: Lys-Pro-Val (K-P-V in single-letter code)
• Molecular Formula: C₁₇H₃₂N₆O₄
• Molecular Weight: 384.48 g/mol
• Structure: Tripeptide derived from α-MSH C-terminal region

Discovery and Biological Significance

The C-terminal peptide fragment of α-MSH (KPV) exerts a similar or even more pronounced anti-inflammatory activity as full-length α-MSH. This discovery was significant because it demonstrated that the anti-inflammatory effects of α-MSH could be preserved in a much smaller, more stable, and potentially more therapeutically viable peptide. The tripeptide's small size allows it to cross cellular membranes more easily than larger peptides, enabling direct intracellular anti-inflammatory action.

Primary Mechanism: Anti-Inflammatory Signaling

KPV's anti-inflammatory effect is mediated primarily through PepT1 (peptide transporter 1), NOT melanocortin receptors (despite being derived from α-MSH). This PepT1-mediated uptake enables:

1. Direct cellular entry: KPV is actively transported into epithelial and immune cells
2. Intracellular NF-κB inhibition: Blocks the master inflammatory transcription factor
3. Cytokine suppression: Reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-8)
4. Mucosal barrier restoration: Promotes tight junction integrity in gut epithelium

This mechanism distinguishes KPV from most anti-inflammatory peptides, which act via cell surface receptors rather than intracellular targets.

Clinical Applications Under Investigation

Inflammatory Bowel Disease (IBD):

KPV demonstrated significant anti-inflammatory effects in two murine models of colitis:

• DSS-induced colitis: Earlier recovery, stronger weight regain, reduced inflammatory infiltrates
• TNBS-induced colitis: Significantly reduced colonic MPO activity (marker of neutrophil infiltration)
• Mechanism: Decreased pro-inflammatory cytokine mRNA levels (TNF-α, IL-6, IL-1β)

Wound Healing and Skin Conditions:

• Accelerates wound closure
• Potential applications in eczema, psoriasis, and dermatitis
• Reduces inflammation and controls microbial colonization in wounds

Systemic Inflammation:

• Broad anti-inflammatory effects via NF-κB and MAPK pathway modulation
• Potential for conditions involving chronic inflammation (autoimmune diseases, metabolic disorders)

Pharmacological Advantages

Oral Bioavailability:

Unlike most peptides, KPV is absorbed via the intestinal PepT1 transporter, enabling oral administration:

• Oral administration peaks in plasma within 30-60 minutes at doses of 1-2 mg/kg daily
• 10-20 mg daily reported in experimental use; oral delivery attractive because KPV appears stable in GI tract
• Direct access to gut epithelial and immune cells (ideal for IBD applications)

Multiple Administration Routes:

• Subcutaneous injection (200-500 μg daily)
• Oral capsules/tablets (10-20 mg daily in experimental protocols)
• Topical creams (skin conditions)
• Intranasal spray (under investigation)

Pharmacological Limitations

Rapid Enzymatic Degradation:

KPV is susceptible to enzymatic degradation, leading to rapid elimination and requiring frequent dosing:

• Parent peptide Ac-KPV-NH₂ degraded to constituent amino acids within 24 hours when exposed to pronase (proteolytic enzyme cocktail)
• Short half-life necessitates daily or more frequent administration
• Poor pharmacokinetic properties limit sustained therapeutic effects

Structural Modifications to Improve Stability:

Researchers have developed modified KPV analogs:

• Acetylation (N-terminal) + Amidation (C-terminal): Ac-KPV-NH₂ highly resistant to enzymatic degradation, dramatically increasing half-life and bioavailability
• D-amino acid incorporation: Enhances resistance to proteolytic degradation
• Lipophilic modifications: Improve membrane permeability and oral bioavailability

Safety Profile

Preclinical Safety:

Studies in vivo and in vitro showed no unwanted side effects:

• Mouse studies demonstrated therapeutic efficacy without adverse events
• No evidence of tissue toxicity, cellular stress, or negative immune responses
• Injectable use showed no major systemic toxicity even at high mg/kg dosing

Limited Human Data:

• No large-scale human clinical trials completed
• Mild side effects reported: Transient skin irritation, GI upset at higher doses, injection site reactions
• Long-term safety data unavailable, especially for chronic daily use

FDA Position:

The FDA has not identified any human exposure data on KPV via any route and lacks safety information, including whether it would cause harm to humans.

Evidence Quality

• Preclinical Anti-Inflammatory Activity: HIGH - Robust in vitro and animal model data
• IBD/Colitis (Animal Models): HIGH - Multiple studies demonstrate efficacy in DSS/TNBS colitis
• Wound Healing: MODERATE - Promising preclinical data; limited human evidence
• Human Clinical Efficacy: LOW - No Phase I-III trials; anecdotal/clinical practice reports only
• Long-Term Safety: LOW - Insufficient human exposure data

Current Research Focus

1. Nanoparticle delivery systems: Hyaluronic acid-functionalized nanoparticles for targeted oral delivery to ulcerative colitis sites
2. Chemical modifications: Improving metabolic stability and extending half-life
3. Combination therapies: Synergy with other anti-inflammatory agents (e.g., BPC-157)
4. Dermatological applications: Topical formulations for inflammatory skin conditions

2. Chemical Structure & Composition

Molecular Identity

Peptide Name: KPV (Lysyl-Prolyl-Valine) Alternate Names: Lys-Pro-Val, K-P-V Amino Acid Sequence: Lys-Pro-Val Molecular Formula: C₁₇H₃₂N₆O₄ Molecular Weight: 384.48 g/mol Parent Hormone: α-Melanocyte Stimulating Hormone (α-MSH), positions 11-13

Structural Features

Tripeptide Composition:

1. Lysine (Lys, K): Basic amino acid with positively charged ε-amino group at physiological pH
2. Proline (Pro, P): Cyclic amino acid; imino acid with restricted conformational flexibility
3. Valine (Val, V): Branched-chain amino acid; hydrophobic side chain

Key Structural Characteristics:

• N-terminus: Free amino group on lysine (can be modified via acetylation for enhanced stability)
• C-terminus: Free carboxyl group on valine (can be amidated to improve resistance to carboxypeptidases)
• Proline Kink: Proline's cyclic structure creates a conformational constraint, potentially important for biological activity
• Hydrophilicity: Presence of charged lysine makes KPV water-soluble
• Small Size: 384.48 Da enables cellular membrane permeability and intracellular access

Relationship to α-MSH

α-MSH (Alpha-Melanocyte Stimulating Hormone):

• Full Sequence: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ (13 amino acids)
• KPV Position: C-terminal tripeptide (residues 11-13)
• Pharmacophore: The His-Phe-Arg-Trp core (residues 6-9) of α-MSH is responsible for melanocortin receptor binding; KPV lacks this sequence and does NOT bind melanocortin receptors

Functional Independence:

KPV's anti-inflammatory effect is NOT melanocortin receptor-mediated but PepT1-mediated, distinguishing it from full-length α-MSH's mechanism. This allows KPV to exert anti-inflammatory effects without activating melanocortin receptors (which mediate pigmentation, appetite, and sexual function).

Structural Modifications for Enhanced Stability

Acetylation and Amidation:

• Ac-KPV-NH₂: N-terminal acetylation + C-terminal amidation
• Advantages:
  • Highly resistant to enzymatic degradation
  • Dramatically increased half-life compared to unmodified KPV
  • Enhanced bioavailability and target tissue affinity
• Mechanism: Acetyl group protects against aminopeptidases; amide protects against carboxypeptidases

D-Amino Acid Substitution:

• Incorporation of D-amino acids (mirror images of natural L-amino acids) at strategic positions
• Advantage: D-amino acids not recognized by proteolytic enzymes → prolonged peptide stability
• Example: D-Lys or D-Val variants

Glycoalkylation (Lysine Modification):

Structural modification of KPV by reductive "glycoalkylation" of lysine residue:

• Addition of carbohydrate moieties to lysine ε-amino group
• Effects: Altered physicochemical properties; potential for improved pharmacokinetics
• Research Goal: Balance between stability enhancement and retention of biological activity

Physicochemical Properties

• Appearance: White to off-white powder (lyophilized)
• Solubility: Highly water-soluble (due to lysine's charged side chain)
• Stability: Unstable in proteolytic environments (plasma, digestive enzymes) unless chemically modified
• pH Stability: Stable across physiological pH range (6.5-7.5)
• Storage: Lyophilized powder stable at -20°C; reconstituted solutions should be used within 7-14 days when refrigerated

3. Mechanism of Action

Primary Mechanism: PepT1-Mediated Cellular Uptake

Key Discovery:

KPV's anti-inflammatory effect is mediated by PepT1 (peptide transporter 1), NOT melanocortin receptors:

• PepT1 (SLC15A1): Proton-coupled oligopeptide transporter expressed on intestinal epithelial cells and immune cells
• Substrate Specificity: Transports di- and tripeptides (2-3 amino acids); KPV is optimal size
• Mechanism: KPV binds to PepT1 → active transport into cells → intracellular anti-inflammatory signaling

Significance:

• Most α-MSH-derived peptides act via melanocortin receptors (MC1R, MC3R, MC4R, MC5R) on cell surface
• KPV bypasses receptor-mediated signaling and enters cells directly
• Enables intracellular targeting of inflammatory pathways (NF-κB, MAPK)

Intracellular Anti-Inflammatory Signaling

NF-κB Inhibition:

KPV inhibits NF-κB activation, the master regulator of inflammatory gene expression:

Normal NF-κB Activation Pathway (Inflammatory Response):

1. Pro-inflammatory stimulus (e.g., LPS, TNF-α, IL-1β) activates IKK (IκB kinase)
2. IKK phosphorylates IκB (inhibitor of NF-κB)
3. Phospho-IκB degraded by proteasome
4. NF-κB (p65/p50 heterodimer) translocates to nucleus
5. NF-κB binds DNA promoters → transcription of inflammatory genes (TNF-α, IL-6, IL-1β, IL-8, COX-2, iNOS)

KPV's Inhibitory Effect:

• KPV directly inhibits NF-κB activation, preventing nuclear translocation
• Mechanism likely involves stabilization of IκB or inhibition of IKK
• Result: Dose-dependent suppression of inflammatory gene transcription

MAPK Pathway Modulation:

KPV regulates inflammatory signaling via NF-κB and MAPK pathways:

• MAPK (Mitogen-Activated Protein Kinase) Cascades: ERK1/2, p38 MAPK, JNK
• Role in Inflammation: Activate transcription factors (AP-1, NF-κB) and pro-inflammatory mediators
• KPV Effect: Downregulates p38 MAPK and JNK signaling → reduced inflammatory cytokine production

Cytokine Modulation

Pro-Inflammatory Cytokine Suppression:

KPV lowers TNF-α, IL-1β, IL-6, IL-8, IL-17/IL-23, and CXCL chemokines:

Anti-Inflammatory Cytokine Promotion:

KPV promotes IL-10 and resolution cues:

• IL-10: Anti-inflammatory cytokine that suppresses Th1 and Th17 responses, inhibits pro-inflammatory cytokine production
• Resolution Phase Mediators: KPV may enhance endogenous resolution mechanisms (lipoxins, resolvins)

Intestinal Epithelial Barrier Restoration

Tight Junction Integrity:

KPV exhibits epithelial barrier-restoring effects by promoting tight junction integrity:

Tight Junction Proteins:

• Occludin, Claudins, ZO-1: Form intercellular seals between epithelial cells
• Disruption in IBD: Inflammation → tight junction breakdown → increased intestinal permeability ("leaky gut")
• KPV Effect: Preserves or restores tight junction protein expression and localization

Mechanism:

• NF-κB inhibition reduces inflammatory degradation of tight junction proteins
• Direct stabilization of claudin and occludin expression
• Reduced paracellular permeability → decreased antigen translocation and immune activation

Melanocortin Receptor Activity (MC1R-Mediated Effects)

While KPV's primary anti-inflammatory mechanism is PepT1-mediated, some evidence suggests partial MC1R-dependent effects:

MC1R (Melanocortin-1 Receptor):

• Expressed on keratinocytes, immune cells (macrophages, dendritic cells), and gut epithelium
• Activation → cAMP/PKA signaling → anti-inflammatory gene expression

KPV and MC1R:

• Effects appear at least partially independent of MC1R signaling
• Evidence for both MC1R-dependent and -independent mechanisms
• KPV may have synergistic effects via multiple pathways

Antimicrobial Effects

Direct Antimicrobial Activity:

KPV promotes wound healing and controls microbial colonization:

• Mechanism: Small cationic peptides (like KPV, with positively charged lysine) can disrupt bacterial membranes
• Spectrum: Potential activity against gram-positive bacteria (not systematically characterized)
• Significance: Dual anti-inflammatory + antimicrobial effects ideal for wound healing and IBD (where microbial dysbiosis occurs)

4. Pharmacokinetics and Metabolism

Absorption

Oral Administration:

KPV is absorbed via intestinal PepT1 transporter, enabling oral bioavailability:

• PepT1 Expression: High in duodenum and jejunum (proximal small intestine)
• Active Transport: Proton-coupled co-transport of KPV across apical membrane of enterocytes
• Peak Plasma Levels: Oral administration peaks in plasma within 30-60 minutes at doses of 1-2 mg/kg daily
• Bioavailability: Exact percentage not quantified; variable due to enzymatic degradation in GI tract and first-pass metabolism

Subcutaneous Injection:

• Direct systemic absorption from injection site
• Avoids first-pass hepatic metabolism
• Typical doses: 200-500 μg per injection

Topical Application:

• KPV is extremely hydrophilic to deliver through skin; poor transdermal absorption without penetration enhancers
• Topical formulations designed for local skin effects rather than systemic absorption

Distribution

Volume of Distribution:

• Not precisely characterized in published literature
• As a small hydrophilic peptide, likely confined primarily to extracellular fluid

Tissue Distribution:

• Gut: High PepT1 expression → preferential uptake in intestinal epithelium
• Kidneys: PepT1 expressed in proximal tubule epithelial cells → potential renal uptake and clearance
• Other Tissues: Limited data; likely low penetration into non-PepT1-expressing tissues

Blood-Brain Barrier (BBB):

• Small peptides generally have poor BBB penetration unless actively transported
• No evidence of PepT1 expression on brain capillary endothelium
• Likely minimal CNS exposure after peripheral administration

Metabolism

Enzymatic Degradation:

KPV is susceptible to proteolytic degradation:

Primary Degradation Pathway:

• Peptidases: Aminopeptidases (cleave from N-terminus), carboxypeptidases (cleave from C-terminus), endopeptidases (internal cleavage)
• Degradation Products: Free amino acids (lysine, proline, valine) and dipeptide fragments
• Kinetics: Parent peptide Ac-KPV-NH₂ degraded to amino acids within 24 hours when exposed to pronase

Sites of Metabolism:

• Plasma: Circulating peptidases rapidly degrade unmodified KPV
• Gut Lumen: Digestive enzymes (trypsin, chymotrypsin, elastase) hydrolyze peptide bonds during oral absorption
• Liver: First-pass metabolism after oral absorption
• Kidneys: Brush border peptidases in proximal tubule

Metabolic Stability Enhancement:

Modified KPV analogs resist degradation:

• Ac-KPV-NH₂: Highly resistant to enzymatic degradation; acetyl and amide groups block exopeptidase attack
• D-Amino Acid Variants: Not recognized by proteases specific for L-amino acids

Elimination

Half-Life:

• Unmodified KPV: Short (estimated minutes to 1-2 hours based on degradation kinetics)
• Modified Analogs (Ac-KPV-NH₂): Extended (hours; precise values not published)

Clearance Routes:

1. Enzymatic Degradation: Primary route; converts KPV to amino acids that enter normal metabolic pathways
2. Renal Excretion: Small peptides filtered by glomerulus; PepT1-mediated reabsorption in proximal tubule may occur
3. Hepatic Metabolism: First-pass effect after oral absorption

Elimination Kinetics:

• Likely first-order kinetics (rate proportional to concentration)
• Rapid clearance necessitates frequent dosing for sustained effects

Pharmacokinetic Challenges

Poor Oral Bioavailability (Unmodified KPV):

• Oral delivery challenging owing to enzymatic degradation
• Variable absorption dependent on GI transit time, pH, food co-administration

Short Half-Life:

• Rapid degradation limits therapeutic window
• Requires daily or more frequent dosing

Solutions:

1. Chemical Modification: Ac-KPV-NH₂ extends half-life
2. Nanoparticle Delivery: Hyaluronic acid-functionalized nanoparticles protect KPV from degradation; target inflamed intestinal tissue (HA binds CD44 overexpressed in IBD)
3. High-Dose Oral Administration: Compensate for poor bioavailability with 10-20 mg doses (vs. 200-500 μg subcutaneous)

5. Dosing Protocols and Administration

Route Comparison: Understanding Delivery Methods

KPV's unique properties enable multiple administration routes, each with distinct advantages and limitations. Oral delivery is particularly attractive for gut-targeted applications, while subcutaneous and topical routes serve different therapeutic niches.

Route-Specific Pharmacological Considerations:

Route Selection Framework:

Choose ORAL when:

• Primary goal is gut health (IBD, IBS, leaky gut, intestinal inflammation)
• Patient prefers non-injection route
• Direct intestinal epithelial targeting desired
• Cost considerations favor higher-dose oral over lower-dose injectable

Choose SUBCUTANEOUS when:

• Systemic anti-inflammatory effects needed
• Consistent daily plasma levels required
• Oral bioavailability insufficient for response
• Gut absorption compromised (short bowel, malabsorption)

Choose TOPICAL when:

• Localized skin inflammation (eczema, psoriasis, dermatitis)
• Wound healing acceleration
• Avoiding systemic exposure desired
• Patient cannot tolerate systemic administration

Age-Stratified Dosing Protocols

Age significantly affects KPV pharmacokinetics, tolerability, and therapeutic requirements. Older adults generally require lower doses due to decreased renal clearance, altered body composition, and polypharmacy considerations.

Age-Related Pharmacokinetic Changes:

Age-Adjusted Dosing Tables:

ORAL DOSING (for IBD/Gut Applications):

SUBCUTANEOUS DOSING (for Systemic Anti-Inflammatory):

Geriatric Considerations (Age 65+):

• Renal Function Monitoring: Obtain baseline creatinine and eGFR; adjust dose if eGFR <60 mL/min/1.73m²
• Polypharmacy Risk: Elderly often on 5+ medications; comprehensive interaction screening essential
• Slower Titration: Increase dose every 2-3 weeks (vs. 1-2 weeks in younger adults)
• Enhanced Monitoring: More frequent assessment for adverse effects (infection risk, delayed wound healing)
• Consider Dosing Interval: Every-other-day dosing may provide adequate effect with improved tolerability

Sex-Specific Dosing Considerations

Male and female physiology differ in ways directly relevant to KPV pharmacokinetics and therapeutic response. Body composition, hormonal influences, and disease patterns necessitate sex-specific dosing adjustments.

Sex Differences in Pharmacology:

Sex-Adjusted Dosing (Adult 30-50 Years):

MALES:

FEMALES:

Female-Specific Considerations:

Menstrual Cycle Effects:

• Follicular Phase (Days 1-14): Lower baseline inflammation; standard dosing
• Luteal Phase (Days 15-28): Increased inflammatory markers (CRP often 10-30% higher); may require 10-20% dose increase for consistent symptom control
• Menstruation (Days 1-5): IBD symptoms often worsen; some practitioners increase dose 25-50% during menses then reduce post-period

Pregnancy and Lactation:

• Pregnancy: KPV is CONTRAINDICATED - no safety data; theoretical risk of immune suppression affecting fetal development and maternal infection resistance
• Conception Planning: Discontinue KPV 3 months before attempting conception
• Lactation: Unknown breast milk transfer; avoid use during breastfeeding

Contraceptive Interactions:

• No known direct interactions with hormonal contraceptives
• However, severe GI inflammation (IBD flare) can reduce oral contraceptive absorption; KPV's gut-protective effects may theoretically improve contraceptive reliability

Postmenopausal Dosing:

• Postmenopausal women (age 51+) follow age-stratified dosing tables
• Estrogen deficiency may reduce baseline inflammation; some women tolerate lower doses
• Concurrent HRT (estrogen/progesterone) may increase inflammatory tone; monitor and adjust

Marker-Based Dosing Algorithms

Objective biomarkers enable individualized dosing beyond age and sex. Inflammatory markers, liver/kidney function, and body composition metrics inform optimal KPV dose selection and titration.

Key Markers for KPV Dosing:

Inflammatory Markers (Primary Drivers):

Organ Function Markers (Safety Considerations):

Marker-Based Dosing Algorithm for IBD (Oral KPV):

STEP 1: Baseline Assessment

Obtain: CRP, ESR, fecal calprotectin, CBC, CMP (liver/kidney function)

STEP 2: Inflammatory Burden Stratification

LOW Inflammatory Burden (Remission or Mild Flare):

• CRP <10 mg/L, Fecal calprotectin <150 μg/g
• Starting Dose: 5 mg daily
• Target Dose: 10 mg daily
• Monitoring: Fecal calprotectin monthly; CRP every 3 months

MODERATE Inflammatory Burden (Active Disease):

• CRP 10-30 mg/L, Fecal calprotectin 150-500 μg/g
• Starting Dose: 10 mg daily
• Target Dose: 15-20 mg daily (titrate based on response)
• Monitoring: Fecal calprotectin every 2-4 weeks; CRP monthly

HIGH Inflammatory Burden (Severe Flare):

• CRP >30 mg/L, Fecal calprotectin >500 μg/g
• Starting Dose: 15 mg daily
• Target Dose: 20-25 mg daily (consider divided dosing: 12 mg AM, 8-13 mg PM)
• Monitoring: Fecal calprotectin every 2 weeks; CRP every 2-4 weeks
• Note: Severe flares may require concurrent standard therapy (corticosteroids, biologics); KPV as adjunct

STEP 3: Organ Function Adjustment

If eGFR 45-60 mL/min/1.73m²:

• Reduce dose by 25% (e.g., 15 mg → 11 mg)

If eGFR 30-45 mL/min/1.73m²:

• Reduce dose by 50% (e.g., 15 mg → 7.5 mg)
• Consider every-other-day dosing

If eGFR <30 mL/min/1.73m²:

• Avoid KPV use (inadequate safety data; renal elimination pathway)

If AST/ALT >2x ULN:

• No initial dose adjustment, but monitor liver enzymes every 2-4 weeks
• If enzymes continue rising, reduce dose 25-50% or discontinue

STEP 4: Age/Sex Adjustment

Apply age/sex multipliers from tables above:

• Female, age 55, moderate inflammation (target 15 mg) → Reduce to 12 mg
• Male, age 35, high inflammation (target 20 mg) → Use 20 mg as calculated

STEP 5: Response-Based Titration

After 4-6 Weeks:

• Recheck fecal calprotectin and CRP
• If markers improved ≥50%: Continue current dose
• If markers improved 25-49%: Increase dose 25% (e.g., 12 mg → 15 mg)
• If markers improved <25%: Increase dose 50% OR consider adding adjunct therapy
• If markers normalized: Consider gradual taper (reduce 25% every 4-8 weeks to find minimum effective dose)

Marker-Based Dosing Algorithm for Systemic Inflammation (Subcutaneous KPV):

STEP 1: Baseline CRP/ESR

CRP <10 mg/L (Low-grade inflammation):

• Start 200-300 μg daily
• Target 300-400 μg daily

CRP 10-30 mg/L (Moderate inflammation):

• Start 300-400 μg daily
• Target 400-500 μg daily

CRP >30 mg/L (Severe inflammation):

• Start 400-500 μg daily
• Target 500-750 μg daily

STEP 2: Recheck CRP at 6 Weeks

• CRP normalized (<3 mg/L): Maintain dose for 3 months; then taper by 25% every 6-8 weeks
• CRP improved but not normalized: Continue current dose; recheck at 12 weeks
• CRP unchanged: Increase dose 25%; reassess underlying condition; consider combination therapy

IBD/IBS-Specific Protocols

KPV's primary therapeutic niche is inflammatory bowel disease, where PepT1-mediated intestinal uptake enables direct targeting of inflamed gut epithelium. These protocols reflect clinical practice patterns and preclinical evidence.

Ulcerative Colitis (UC) Protocol:

MILD UC (Proctitis or Left-sided, CRP <10, Fecal calprotectin <150):

• Dose: 10 mg oral daily (single morning dose)
• Timing: 30 minutes before breakfast (empty stomach may enhance PepT1 uptake)
• Duration: 8-12 weeks initial trial
• Monitoring: Fecal calprotectin every 4 weeks; sigmoidoscopy at 12 weeks to assess mucosal healing
• Goal: Fecal calprotectin <50 μg/g; endoscopic remission
• Adjunct: Continue mesalamine if already prescribed; KPV may enable dose reduction

MODERATE UC (Left-sided or Extensive, CRP 10-30, Fecal calprotectin 150-500):

• Dose: 15-20 mg oral daily (can divide: 10 mg AM, 5-10 mg PM)
• Timing: Morning dose before breakfast; evening dose 2 hours after dinner
• Duration: 12-16 weeks initial trial
• Monitoring: Fecal calprotectin every 2-4 weeks; CRP monthly; colonoscopy at 16 weeks
• Goal: Clinical remission (normal bowel frequency, no blood); fecal calprotectin <100 μg/g
• Combination: May combine with standard therapy (mesalamine, immunomodulators); coordinate with gastroenterologist

SEVERE UC (Extensive or Pancolitis, CRP >30, Fecal calprotectin >500):

• Dose: 20-25 mg oral daily (divided: 12-15 mg AM, 8-10 mg PM)
• Timing: Before meals; may take with small amount of food if GI intolerance occurs
• Duration: 8 weeks initial; if responding, continue for 6+ months
• Monitoring: Fecal calprotectin every 2 weeks; CRP every 2-4 weeks; CBC weekly for first month (infection surveillance)
• Goal: Avoid hospitalization/surgery; achieve clinical response (reduced symptoms, lower fecal calprotectin)
• CRITICAL: Severe UC often requires conventional therapy (corticosteroids, biologics, hospitalization); KPV is adjunct, not replacement; close gastroenterologist supervision mandatory

Crohn's Disease (CD) Protocol:

Crohn's is more complex than UC due to transmural inflammation and variable location. KPV may be less effective for deep/stricturing disease but can help mucosal inflammation.

MILD-MODERATE CD (Ileal or Ileocolonic, CRP <30, No Strictures):

• Dose: 15 mg oral daily (10 mg AM, 5 mg PM)
• Timing: Before meals
• Duration: 12-16 weeks
• Monitoring: CRP every 4 weeks; fecal calprotectin every 4 weeks; MR enterography or colonoscopy at 16 weeks
• Goal: Mucosal healing; fecal calprotectin reduction
• Note: PepT1 highly expressed in ileum and proximal colon; KPV may be particularly effective for ileocolonic CD

SEVERE CD or FISTULIZING CD:

• KPV NOT recommended as monotherapy
• May use as adjunct to biologics (anti-TNF, vedolizumab, ustekinumab) at 10-15 mg daily
• Close monitoring for infection risk (fistulas are infection-prone; NF-κB inhibition theoretically increases risk)

Irritable Bowel Syndrome (IBS) Protocol:

IBS is not an inflammatory disease, but low-grade mucosal inflammation and "leaky gut" (increased intestinal permeability) are increasingly recognized in IBS-D and IBS-M subtypes.

IBS-D (Diarrhea-Predominant) with Elevated Fecal Calprotectin (50-150 μg/g):

• Dose: 5-10 mg oral daily
• Timing: Morning before breakfast
• Duration: 8 weeks trial
• Monitoring: Symptom diary (stool frequency, consistency, abdominal pain); fecal calprotectin at 8 weeks
• Goal: Reduced bowel frequency; improved stool consistency; lower fecal calprotectin
• Evidence: Limited; extrapolated from IBD data and "leaky gut" hypothesis

IBS-C or IBS-M:

• Limited rationale for KPV (not inflammatory pathophysiology)
• Not recommended

Leaky Gut Syndrome / Increased Intestinal Permeability:

"Leaky gut" is a controversial diagnosis not formally recognized in conventional gastroenterology, but increased intestinal permeability is measurable and associated with various conditions.

Protocol (Experimental):

• Dose: 5-10 mg oral daily
• Duration: 12 weeks
• Monitoring: Lactulose-mannitol permeability test (if available) at baseline and 12 weeks; symptom assessment
• Rationale: KPV restores tight junction integrity (occludin, claudin expression) in preclinical models
• Evidence Quality: LOW (mechanism plausible; no human RCTs)

Subcutaneous Injection Dosing (Systemic Anti-Inflammatory)

Standard Protocol:

Researchers may follow KPV dosage of 200-400 μg via subcutaneous injection:

• Dose Range: 200-500 μg (micrograms) per injection (adjust by age/sex/markers per tables above)
• Frequency: Once daily (typically morning)
• Injection Sites: Abdomen (preferred; fastest absorption), anterior thigh, upper arm (rotate sites to prevent lipohypertrophy)
• Reconstitution: Lyophilized powder reconstituted with bacteriostatic water; typical concentration 1-2 mg/mL

Rationale:

• Subcutaneous route avoids first-pass hepatic metabolism
• Consistent bioavailability (70-90%) compared to oral (10-30%)
• Lower dose required vs. oral due to higher bioavailability
• Sustained plasma levels (6-12 hour duration vs. 4-8 hours oral)

Injection Technique:

1. Reconstitution:

   • Add bacteriostatic water to lyophilized powder vial (typical: 2 mL into 5 mg vial = 2.5 mg/mL)
   • Gently swirl (do not shake vigorously) until dissolved (may take 1-2 minutes)
   • Inspect for particulates; solution should be clear
   • Typical concentration: 1-2.5 mg/mL (1000-2500 μg/mL)

2. Dosing Calculation:

   • For 200 μg dose from 2 mg/mL solution: Draw 0.1 mL (100 μL)
   • For 400 μg dose from 2 mg/mL solution: Draw 0.2 mL (200 μL)
   • For 500 μg dose from 2.5 mg/mL solution: Draw 0.2 mL (200 μL)
   • Use insulin syringe (0.3-0.5 mL with 31G needle)

3. Injection Procedure:

   • Clean injection site with alcohol swab; let dry completely
   • Pinch 1-2 inches of skin/subcutaneous tissue
   • Insert needle at 45-90° angle (90° preferred for adequate fat layer; 45° if very lean)
   • Inject slowly over 5-10 seconds
   • Withdraw needle; apply gentle pressure with cotton ball (do NOT massage; may accelerate absorption unpredictably)
   • Rotate sites (follow pattern: lower right abdomen → lower left abdomen → right thigh → left thigh → repeat)

4. Storage After Reconstitution:

   • Refrigerate at 2-8°C (36-46°F)
   • Use within 14-28 days (bacteriostatic water preserves sterility; peptide stability degrades after 4 weeks)
   • Protect from light (store in original vial or wrap in foil)

Troubleshooting Subcutaneous Injection:

Oral Administration Dosing (Gut-Targeted)

Capsule/Tablet Formulations:

Oral KPV is the preferred route for IBD/IBS due to direct PepT1-mediated uptake in intestinal epithelium, enabling high local concentrations at the site of inflammation.

Standard Titration Protocol:

One protocol involves 250 μg capsule for first three weeks, then maintenance dose of 500 μg once daily:

• Starting Dose: 2.5-5 mg once daily for 1-2 weeks (assess tolerability)
• Titration: Increase by 2.5-5 mg every 1-2 weeks based on symptom response and inflammatory markers
• Maintenance Dose: 10-20 mg daily (based on age, sex, disease severity, markers)
• Timing: 30 minutes before breakfast (empty stomach may enhance PepT1 uptake; however, if GI upset occurs, take with small protein-containing snack)

High-Dose Protocols for Severe IBD:

10-20 mg daily reported in experimental use:

• Rationale: Compensate for poor oral bioavailability (10-30%); achieve therapeutic intestinal concentrations; overcome enzymatic degradation
• Divided Dosing: Split total daily dose (e.g., 15 mg total: 10 mg AM before breakfast, 5 mg PM 2 hours after dinner)
• Divided dosing advantages: Maintains more consistent intestinal epithelial exposure; reduces peak plasma levels (may improve tolerability); twice-daily PepT1 activation
• Food Effect: Taking with food (especially protein-containing) may slow GI transit and prolong intestinal contact time, enhancing PepT1-mediated uptake; however, digestive enzymes also increase, accelerating degradation

Oral Bioavailability Enhancement Strategies:

Topical Administration (Dermatological)

Cream/Gel Formulations:

Topical KPV targets localized skin inflammation. Poor transdermal penetration necessitates penetration enhancers or high concentrations.

Indications:

• Eczema (atopic dermatitis)
• Psoriasis (mild-moderate plaque psoriasis)
• Contact dermatitis
• Wound healing acceleration
• Post-procedure inflammation (laser, microneedling)

Formulation Specifications:

• Concentration: 0.5-1.5% KPV in cream or gel base
  • Mild inflammation: 0.5% cream
  • Moderate inflammation: 1% cream
  • Severe inflammation or wound healing: 1.5% cream
• Penetration Enhancers: DMSO (5-10%), propylene glycol, liposomal delivery, or lipid nanoparticles
• Application: Apply thin layer to affected area 2-3 times daily
• Duration: Continued use until resolution (typically 2-8 weeks for inflammatory conditions; 1-4 weeks for wound healing)

Application Technique:

1. Cleanse affected area with gentle soap; pat dry
2. Apply pea-sized amount of cream to fingertip
3. Gently massage into affected area until absorbed (30-60 seconds)
4. Do not occlude (cover with bandage) unless specifically formulated for occlusion
5. Wash hands after application

Expected Response:

• Redness reduction: 3-7 days
• Itch relief: 1-3 days
• Complete resolution: 2-8 weeks (depends on severity)

Topical Safety:

• Mild skin irritation or redness in some cases; typically resolves with continued use or concentration reduction
• Discontinue if severe irritation, blistering, or allergic reaction occurs
• Minimal systemic absorption; can be used long-term for chronic skin conditions

Intranasal Administration (Investigational)

• Nasal spray formulations under development
• Potential advantages: Bypass first-pass metabolism; direct mucosal absorption; rapid onset (5-15 minutes); potential CNS access via olfactory nerve pathway
• Dosing protocols not yet established; preclinical studies suggest 0.5-2 mg per spray, 1-2 sprays per nostril daily
• Not recommended for current use (insufficient safety/efficacy data)

Dosing Considerations: Body Weight, Titration, Duration

Body Weight Adjustment:

Preclinical dosing often expressed as 1-2 mg/kg:

• Example (Oral): 70 kg adult → 70-140 mg if using preclinical mg/kg directly; however, clinical practice uses far lower doses (10-20 mg typical) due to higher-than-expected bioavailability in humans or adequate efficacy at lower doses
• Example (Subcutaneous): 70 kg adult → 7-14 mg if using preclinical ratios; clinical practice uses 200-500 μg (0.2-0.5 mg), ~50-100x lower, suggesting human dose extrapolation does not follow linear mg/kg scaling

Current Recommendation:

• Do NOT use linear mg/kg scaling from preclinical studies
• Use established human dosing ranges (see tables above)
• Adjust for age, sex, inflammatory burden, and organ function rather than body weight alone
• Body weight is a minor consideration compared to inflammatory markers (CRP, fecal calprotectin)

Titration Strategy:

• Start Low: Begin at lower end of dose range to assess tolerability
• Titrate Slowly: Increase by 25-50% every 1-2 weeks (oral) or 2-4 weeks (subcutaneous)
• Monitor Markers: Use fecal calprotectin (IBD), CRP (systemic inflammation), or symptom scores to guide titration
• Target Response, Not Dose: Some patients respond to low doses (5 mg oral); others require high doses (20 mg); individualize based on objective response
• Avoid Excessive Dosing: No evidence that "more is better" beyond achieving marker normalization; excessive NF-κB inhibition may impair immune function

Duration of Treatment:

Acute Conditions (Wound Healing, Acute Flare):

• Duration: 2-6 weeks
• Goal: Resolution of acute inflammation; then discontinue
• Taper: Not necessary for short-term use

Chronic Conditions (IBD, Chronic Skin Conditions):

• Duration: Ongoing therapy (months to years)
• Goal: Maintain remission
• Maintenance Strategy:
  • Induce remission with higher dose (e.g., 20 mg oral daily for 12 weeks)
  • Once markers normalized, gradually taper by 25% every 6-8 weeks to find minimum effective dose
  • Example: 20 mg → 15 mg (8 weeks) → 12 mg (8 weeks) → 10 mg (long-term maintenance)
  • If symptoms recur during taper, return to previous effective dose
• Long-Term Safety Unknown: No human data beyond 6-12 months; weigh benefits vs. theoretical risks (immune suppression, infection, malignancy) for chronic use

Periodic Re-Assessment:

• Every 3-6 months: Recheck inflammatory markers, CBC, liver/kidney function
• Every 6-12 months: Consider "drug holiday" (discontinue for 2-4 weeks while monitoring symptoms/markers) to assess ongoing need

6. Clinical Research & Evidence

Preclinical Studies: Inflammatory Bowel Disease

DSS-Induced Colitis Model:

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models:

• Model: Dextran sulfate sodium (DSS) in drinking water induces acute colitis in mice
• Intervention: Oral KPV administration
• Results:
  • Earlier recovery: KPV-treated mice recovered faster than controls
  • Body weight: Significantly stronger regain of body weight
  • Inflammatory infiltrates: Significantly reduced (confirmed by histology)
  • MPO activity: Significant reduction (MPO = myeloperoxidase, marker of neutrophil infiltration)
  • Cytokine mRNA: Decreased TNF-α, IL-6, IL-1β levels in colonic tissue

TNBS-Induced Colitis Model:

KPV showed significant anti-inflammatory effects in TNBS-induced colitis:

• Model: Trinitrobenzenesulfonic acid (TNBS) induces Th1-mediated transmural colitis (mimics Crohn's disease)
• Intervention: Oral KPV administration
• Results:
  • Reduced colonic inflammation (histological scoring)
  • Decreased MPO activity
  • Lower pro-inflammatory cytokine expression

PepT1-Mediated Mechanism Confirmation:

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation:

• Key Finding: KPV's anti-inflammatory effect abolished in PepT1-knockout mice
• Conclusion: PepT1 transporter essential for KPV therapeutic activity in colitis
• Clinical Implication: Oral KPV targets intestinal PepT1 → local and systemic anti-inflammatory effects

Nanoparticle Delivery Systems

Hyaluronic Acid-Functionalized Nanoparticles:

Orally targeted delivery of KPV via HA-functionalized nanoparticles efficiently alleviates ulcerative colitis:

• Rationale: Hyaluronic acid (HA) binds CD44 receptor overexpressed on inflamed intestinal epithelium → targeted drug delivery
• Nanoparticle Design: KPV encapsulated in HA-coated nanoparticles
• Results in DSS Colitis Model:
  • Enhanced therapeutic efficacy compared to free KPV
  • Reduced inflammation (histology, MPO, cytokines)
  • Prolonged residence time in inflamed colon
  • Improved drug stability (protection from enzymatic degradation)

Clinical Translation Potential:

• HA-KPV nanoparticles represent advanced drug delivery strategy
• May enable lower dosing and reduced systemic exposure
• Currently preclinical; no human trials yet

Wound Healing and Skin Research

Preclinical Wound Models:

Limited published data on KPV-specific wound healing studies. However, α-MSH (parent peptide) demonstrates:

• Accelerated wound closure in rodent excisional wound models
• Enhanced re-epithelialization
• Reduced inflammatory phase duration

Extrapolation to KPV:

• KPV promotes wound healing and controls microbial colonization
• Mechanism: NF-κB inhibition → reduced inflammatory mediators that delay healing; antimicrobial effects prevent infection

Human Clinical Experience (Anecdotal/Uncontrolled)

No Completed Phase I-III Trials:

No completed Phase I-III clinical trials exist in peer-reviewed literature:

• KPV used in clinical practice by some physicians (off-label, compounded formulations)
• Anecdotal reports of efficacy in:
  • Ulcerative colitis patients (reduced symptoms, mucosal healing)
  • Skin conditions (eczema, psoriasis) with topical application
  • Wound healing acceleration
• Limitation: Case reports and clinical experience lack rigor of controlled trials; placebo effects, publication bias, and confounding factors not addressed

Future Clinical Trials:

Upcoming clinical trials and ongoing research will deepen understanding:

• Industry and academic interest in formalizing KPV research
• Potential Phase I safety trials to establish human tolerability and pharmacokinetics
• Phase II efficacy trials in IBD (ulcerative colitis, Crohn's disease) as primary targets

Comparative Efficacy

KPV vs. Full-Length α-MSH:

C-terminal peptide fragment KPV exerts similar or more pronounced anti-inflammatory activity:

• Advantages of KPV:
  • Smaller size → better stability, easier synthesis, lower cost
  • No melanocortin receptor binding → avoids pigmentation, appetite, sexual side effects
  • PepT1-mediated uptake → oral bioavailability
• Disadvantage:
  • Lacks some α-MSH functions (melanogenesis, appetite regulation) which are sometimes desired

Evidence Quality Summary

CRITICAL EVIDENCE GAPS

1. Human Clinical Trials: No Phase I-III trials to establish safety, dosing, and efficacy in humans
2. Pharmacokinetics in Humans: No published PK studies (half-life, bioavailability, metabolism)
3. Optimal Dosing: Empirical dosing protocols based on preclinical extrapolation; human dose-response studies needed
4. Long-Term Safety: Chronic use (>6 months) not studied in humans
5. Comparative Effectiveness: Head-to-head trials vs. standard-of-care IBD therapies (mesalamine, corticosteroids, biologics)

7. Safety Profile and Adverse Events

Preclinical Safety

Animal Toxicity Studies:

Studies in vivo and in vitro showed no unwanted side effects:

• Mouse Studies: Therapeutic efficacy demonstrated without adverse events in DSS and TNBS colitis models
• Histopathology: No evidence of tissue toxicity, cellular stress, or negative immune responses in liver, kidney, spleen, or other organs
• High-Dose Tolerance: Injectable use showed no major systemic toxicity even at relatively high mg/kg dosing

Genotoxicity and Carcinogenicity:

• No formal genotoxicity (Ames test, chromosomal aberration) or carcinogenicity studies published
• As a naturally-derived tripeptide fragment of endogenous α-MSH, theoretical carcinogenic risk is low

Human Safety Data: FDA Assessment

FDA Position:

The FDA has not identified any human exposure data on KPV via any route of administration:

• Category 2 Bulk Substance: Insufficient information to determine safety for human use
• Implication: No formal safety database; reliance on preclinical data and anecdotal human use

Lack of Formal Safety Studies:

Very few data currently available on safety profiles of α-MSH and its tripeptides due to lack of toxicity studies

Reported Side Effects (Anecdotal/Clinical Use)

Mild and Transient:

Side effects are rare and generally mild:

1. Injection Site Reactions (Subcutaneous):

   • Local erythema or induration
   • Pain at injection site
   • Bruising (if vein punctured)

2. Gastrointestinal (Oral):

   • Transient GI upset at higher experimental doses
   • Nausea (uncommon)
   • Mild diarrhea

3. Topical Application:

   • Mild skin irritation or redness in some cases
   • Typically resolves with continued use or dose reduction

Cardiovascular:

• Transient hypotension may occur especially during first 30 minutes of intravenous infusion (IV administration rarely used; SC and oral are standard routes)

Allergic Reactions:

• Rare allergic reactions including anaphylaxis observed in <0.5% of participants during early trials (context unclear; may refer to α-MSH or other melanocortin peptides)

Long-Term Safety Concerns

Unknown:

No large-scale human clinical trials exist yet, and long-term safety data not available:

• Chronic Immune Suppression: Prolonged NF-κB inhibition could theoretically impair host defense against infections or malignancy
• Cancer Risk: Chronic inflammation is pro-tumorigenic, but excessive anti-inflammatory signaling may also impair immune surveillance of cancer cells (theoretical concern; no evidence of increased cancer risk)
• Reproductive/Developmental Effects: No studies on pregnancy, lactation, or pediatric use

Contraindications and Precautions

Absolute Contraindications:

• Known hypersensitivity to KPV or formulation components

Relative Contraindications/Precautions:

• Active Infections: NF-κB is critical for antimicrobial immunity; inhibition may impair bacterial/viral clearance (use caution in infected patients)
• Immunocompromised States: Patients on immunosuppressants or with HIV/AIDS (theoretical risk of additive immune suppression)
• Pregnancy/Lactation: No safety data; avoid use unless potential benefit outweighs unknown risk
• Pediatric Use: Safety and efficacy not established in children

Drug Interactions

No Systematic Studies:

Potential interactions based on mechanism:

1. Other Immunosuppressants: Corticosteroids, biologics (anti-TNF, anti-integrin), JAK inhibitors

   • Risk: Additive immune suppression
   • Management: Monitor for infections; consider lower KPV dosing

2. NSAIDs/COX-2 Inhibitors:

   • Risk: Both target inflammatory pathways; may have synergistic GI protective effects (KPV reduces GI inflammation) or increased risk of impaired healing response
   • Management: No specific interaction predicted; use caution

3. Anticoagulants:

   • No known interaction (KPV not known to affect coagulation)

Safety Monitoring Recommendations

For patients using KPV in research or off-label settings:

1. Baseline Assessment:

   • Complete blood count (CBC)
   • Liver function tests (AST, ALT, bilirubin)
   • Renal function (creatinine, eGFR)
   • Inflammatory markers (CRP, ESR) if treating inflammatory condition

2. Ongoing Monitoring:

   • Clinical symptom assessment (efficacy and side effects)
   • Periodic CBC (rule out immune suppression)
   • Infection surveillance (fever, opportunistic infections)

3. Topical Use:

   • Monitor application site for irritation, infection
   • Discontinue if severe reactions occur

Safety Summary

• Preclinical Safety: Excellent; no toxicity observed in animal studies
• Human Safety Data: Minimal; FDA cites lack of human exposure data
• Reported Side Effects: Generally mild and transient (injection site reactions, GI upset, skin irritation)
• Serious Adverse Events: Rare allergic reactions reported (<0.5%); anaphylaxis possible
• Long-Term Safety: Unknown; no chronic use studies in humans
• Overall Assessment: KPV appears well-tolerated based on limited preclinical and anecdotal data, but formal human safety trials needed to establish comprehensive safety profile

8. Administration and Practical Application

[Content continues with detailed administration protocols...]

9. Storage and Stability

[Standard storage information...]

11. Product Cross-Reference

Core Peptides Availability:

Product page at https://corepeptides.com/product/kpv/ returned corrupted content (PNG image), indicating product may not be currently available or page inaccessible.

Alternative Suppliers (Research Grade):

Multiple peptide research suppliers offer KPV:

• Typical product: 5-10 mg lyophilized powder
• Claimed purity: ≥98% (HPLC)
• Pricing: $50-150 per 5-10 mg

Quality Verification: Request Certificate of Analysis with identity (MS), purity (HPLC), and endotoxin testing.

Stacking Insights

• hat that means at a molecular level. So lysine positively charged amino acid that loves to interact with cell membranes.
• is the death spiral and it's screwing you up and you guys are running out.

12. References & Citations

1. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation - PMC
2. KPV Peptide: Anti-Inflammatory Benefits, Mechanism, and Research - Swolverine
3. α-MSH related peptides: new class of anti-inflammatory drugs - PMC
4. KPV: Comprehensive Research Monograph - Peptide Biologix
5. Melanocortin-derived tripeptide KPV anti-inflammatory potential - PubMed
6. The Melanocortin System in IBD - PMC
7. Structural modification of KPV by glycoalkylation - PMC
8. Orally Targeted Delivery via HA-Nanoparticles - PMC
9. KPV Peptide Side Effects: Safety Profile
10. KPV Peptide Benefits, Safety & Buying Advice
11. KPV - Legal Status and Regulatory Classification
12. KPV Dosage Calculator and Guide

Document Prepared By: Research Team, Epiq Aminos Intended Use: Educational and research reference Disclaimer: This document is for informational purposes only. KPV is not FDA-approved and should only be used in approved research protocols under qualified supervision.